Skip to main
  1. Stocks
  2. iBio
  3. Forecast
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio is attractive because its lead asset IBIO-610 is backed by unusually strong, internally consistent preclinical data across rodents and NHPs, with up to 98% Activin E inhibition, improved body composition, and evidence that it can preserve lean mass while enhancing semaglutide-driven fat loss and limiting rebound after withdrawal. The thesis is further strengthened by human genetics and emerging competitor human data validating Activin E biology in visceral fat, liver fat, and diabetes protection, while the broader platform adds optionality through IBIO-800, IBIO-600, and the amylin program, each aimed at differentiated, ligand-selective mechanisms in large or less-crowded markets. Financially, the company had about $88.0 million in cash, cash equivalents, and investments in debt securities as of June 30, 2026, with runway extending into 2028, which supports execution through upcoming catalysts including an IND/CTA by year-end 2026 and first-in-human studies in 1H27.

Bears say

iBio is a clinical-stage company with no products generating revenue, persistent operating losses since inception, and a likely need for additional debt or equity funding to support research, regulatory work, and future commercialization, creating meaningful dilution risk. Its pipeline also faces significant clinical uncertainty: activin-pathway safety concerns have been highlighted by pericardial effusions, cardiopulmonary hospitalizations, and other serious adverse events in comparable programs, while iBio’s own candidates still face unresolved questions on dose selection, biomarker strategy, and the ability to compete on endpoints such as MRI-PDFF. On top of that, manufacturing reliance on third parties, competitive pressure from better-capitalized peers, and regulatory, IP, and litigation risks all weaken confidence in long-term value creation.

iBio (IBIO) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

iBio (IBIO) Analyst Forecast & Price Prediction

Get the latest iBio (IBIO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in iBio (IBIO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Strong Buy based on their latest research and market trends.

According to 4 analysts, iBio (IBIO) has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


iBio (IBIO) Analyst Forecast & Price Prediction

Get the latest iBio (IBIO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in iBio (IBIO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IBIO stock data and trends